Investigational New Drugs

, Volume 27, Issue 4, pp 387–388 | Cite as

Major response to sunitinib (Sutene®) in metastatic malignant phyllodes tumor of breast

  • In Hae Park
  • Youngmee Kwon
  • Eun-A Kim
  • Keun Seok Lee
  • Jungsil RoEmail author


Paclitaxel Renal Cell Carcinoma Sunitinib Chondrosarcoma Chest Compute Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by NCC grant No. 0610240-3.


  1. 1.
    Rowell MD, Perry RR, Hsiu JG et al (1993) Phyllodes tumors. Am J Surg 165:376–379 doi: 10.1016/S0002-9610(05)80849-9 PubMedCrossRefGoogle Scholar
  2. 2.
    Reinfuss M, Mitus J, Duda K et al (1996) The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77:910–916 doi: 10.1002/(SICI)1097-0142(19960301)77:5<910::AID-CNCR16>3.0.CO;2-6 PubMedCrossRefGoogle Scholar
  3. 3.
    Tse GM, Putti TC, Lui PC et al (2004) Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 17:827–831 doi: 10.1038/modpathol.3800125 PubMedCrossRefGoogle Scholar
  4. 4.
    Tse GM, Lui PC, Scolyer RA et al (2003) Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol 16:1007–1013 doi: 10.1097/01.MP.0000089907.67419.42 PubMedCrossRefGoogle Scholar
  5. 5.
    Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
  6. 6.
    Patyna S, Laird AD, Mendel DB et al (2006) SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5:1774–1782 doi: 10.1158/1535-7163.MCT-05-0333 PubMedCrossRefGoogle Scholar
  7. 7.
    Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896 doi: 10.1200/JCO.2006.06.3602 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • In Hae Park
    • 1
  • Youngmee Kwon
    • 1
  • Eun-A Kim
    • 1
  • Keun Seok Lee
    • 1
  • Jungsil Ro
    • 1
    Email author
  1. 1.Center for Breast cancerNational Cancer CenterGoyang-siRepublic of Korea

Personalised recommendations